Sputnik 83% Effective Vs Delta, WHO To Approve in Mid-September

The drug developed by the Gamaleya Institute proved to be 94.4% effective against coronavirus delta variant hospitalizations and 83.1% against infection. As the developers of Sptunik V reported on social networks, "this is the highest efficacy compared to Moderna's estimated 76% and Pfizer's 42%."

During the month of July, the medical journal Vaccines had published research carried out by the Gamaleya Center where they demonstrated that Sputnik V is "highly effective against the new variants of COVID-19, including Delta," as highlighted in Sputnik's official Twitter.

RELATED:

Sputnik V Announces a Booster Shot Against the Delta Variant

"Vaccination with Sputnik V has produced protective neutralization titers against new variants, including Alpha B.1.1.7 (first identified in the UK), Beta B.1.351 (first identified in South Africa), Gamma P.1 (first identified in Brazil), Delta B.1.617.2 and B.1.617.3 (first identified in India) and Moscow endemic variants B.1.1.141 and B.1.1.317 with mutations in the receptor binding domain (RBD)," recalled the statement released Wednesday by the Gamaleya Institute.

They also added that "the data confirm that Sputnik V continues to protect against the newly detected variants and retains one of the best safety and efficacy parameters."

Sputnik V, a COVID-19 vaccine developed by Russia, could be approved by the World Health Organization (WHO) by mid-September, WHO Assistant Director-General Mariangela Simao said Wednesday.

"Sputnik V is undergoing legal procedures," she said at a press conference, before adding that the Russian vaccine is being considered for inclusion in the COVAX mechanism, developed by the WHO to achieve equal distribution of vaccines around the world.

"The dates are still uncertain for the completion of the process, but we expect this to happen by mid-September," she said.